Insider · CIK 0002080343
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Files at KLRA (Kailera Therapeutics, Inc.), BRVE (Braveheart Bio, Inc.). First filing -, latest -.
In brief
Jiangsu Hengrui Pharmaceuticals Co., Ltd. files SEC Form 4 as 10% owner at KLRA (Kailera Therapeutics, Inc.), and also at BRVE (Braveheart Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jiangsu Hengrui Pharmaceuticals Co., Ltd. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | CConversion Common Stock | +7,420,091 | - | - | 7,420,091 | Aug 10, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | CConversion Non-voting Series A preferred stockderivative | -32,500,000 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Common Stock | +9,477,719 | - | - | 9,477,719 | Apr 22, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Common Stock | +2,034,133 | - | - | 2,034,133 | Apr 22, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Series A-2 convertible preferred stockderivative | -4,968,789 | $0.00 | $0 | 0 | Apr 22, 2026 |
| Apr 20, 2026 | KLRA Kailera Therapeutics, Inc. | CConversion Series A-2 convertible non-voting preferred stockderivative | -708,814 | $0.00 | $0 | 0 | Apr 22, 2026 |
Questions about Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Answered from the filings on this page, as of the latest one.
Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. buying or selling?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. has 0.
Where does Jiangsu Hengrui Pharmaceuticals Co., Ltd. file Form 4?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has filed Form 4 at KLRA (Kailera Therapeutics, Inc.); BRVE (Braveheart Bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.